2021 China BioMed Innovation and Investment Conference Opening Ceremony
8:30-8:50
第一阶段：致辞
Session I: Welcome Remarks
Moderator
任晋生，中国医药创新促进会2020-2021年度会长、先声药业董事长兼CEO
REN Jinsheng, 2020-2021 Annual Chairman of PhIRDA, CEO and Chairman of the Board of Simcere Pharmaceutical Group
8:30-8:35
主办方致辞
Welcome Remarks by Hosts
李燕, 中国医药创新促进会会长、齐鲁制药集团总裁
LI Yan, Chairman of PhIRDA, President of Qilu Pharmaceutical Group
8:35-8:40
欧冠升，香港交易所集团行政总裁
Nicolas Aguzin, Chief Executive Officer of HKEX
8:40-8:45
苏州市政府领导
Senior Official of Suzhou Municipal Government
8:45-8:50
特别支持单位致辞
Welcome Remarks by Special Supporter
沙雁, 深圳证券交易所党委副书记、总经理
SHA Yan, Deputy Secretary of the Party Committee, President and CEO of Shenzhen Stock Exchange
8:50-10:45
第二阶段：主旨演讲
Session II: Keynote Speeches
Moderator
李佳，中国医药创新促进会候任会长、中国科学院上海药物研究所所长、新药研究国家重点实验室主任
LI Jia, Chairman-elected of PhIRDA, Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Director of State Key Laboratory of Drug Research
8:50-9:05
主旨报告一：面向人民生命健康，科技创新支撑医药产业高质量发展
Technological Innovation Supports High-quality Development of Pharmaceutical Industry for People's Life and Health
报告人：张洪刚, 国家科技部重大专项司副司长
Speaker: ZHANG Honggang, Deputy Director-General of Department of Major Science and Technology Project, Ministry of Science and Technology
9:05-9:30
主旨报告2：AI助力药物研发
Keynote Speech: AI Empowers Drug Research and Discovery
Speaker: JIANG Hualiang, Academician of Chinese Academy of Sciences, 2015-2016 Annual Chairman of PhIRDA, Professor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences
9:30-9:55
主旨报告3：以临床价值为导向的药物研发与科学监管
Keynote Speech: Clinical Value-Oriented Drug R&D and Scientific Administration
报告人：周思源，国家药品监督管理局药品审评中心副主任
Speaker: ZHOU Siyuan, Deputy Director of Center for Drug Evaluation, National Medical Products Administration
9:55-10:20
主旨报告4：中国医药创新发展回顾与展望
Keynote Speech: Review and Prospect of the Development of Pharmaceutical Innovation in China
报告人：宋瑞霖，中国医药创新促进会执行会长
Speaker: SONG Ruilin, Executive President of PhIRDA
10:20-10:45
主旨报告5：新“KPI”下的宏观形势
Keynote Speech: Macroeconomic Conditions under the New "KPI"
报告人：张继强，华泰证券研究所副所长、总量研究负责人、固定收益首席分析师
Speaker: ZHANG Jiqiang, Managing Director and Chief Fixed Income Analyst of Huatai Securities Research Institute
10:45-12:05
第三阶段：专题讨论
Session III: Panel
10:45-11:25
专题讨论1
Panel 1
医药创新产业发展
Trends on Pharmaceutical Innovation Industry
Moderator
陈启宇，中国医药创新促进会2012-2013年度会长、复星国际执行董事兼联席CEO
CHEN Qiyu，2012-2013 Annual Chairman of PhIRDA, Executive Director and Co-CEO of Fosun International
ZHAO Baige, Vice Chair of the 12th NPC Foreign Affairs Committee of the People's Republic of China, Chair of the Advisory Committee of BRI International Think Tank, CASS, Chair of Advisory Committee of RDI
JIANG Hualiang, Academician of Chinese Academy of Sciences, 2015-2016 Annual Chairman of PhIRDA, Professor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences
James XUE, Vice-Chairman of PhIRDA Drug R&D Specialty Committee, Founder, Chairman of the Board, Director and CEO of CANbridge, Vice Director of the China Alliance for Rare Diseases
11:25-12:05
专题讨论2
Panel 2
投资与医药创新发展
Investment and Pharmaceutical Innovation Development
Moderator
宋瑞霖，中国医药创新促进会执行会长
SONG Ruilin，Executive President of PhIRDA
Panelists
康韦， 中国外商投资企业协会副会长、RDPAC执行总裁
KANG Wei，Vice Chair of CAEFI, Managing Director of RDPAC
房健民，中国医药创新促进会药物研发专业委员会副主任委员、荣昌生物CEO兼首席科学官
FANG Jianmin，Vice-Chairman of PhIRDA Drug R&D Specialty Committee, CEO and CSO of RemeGen
王印祥, 中国医药创新促进会药物研发专业委员会副主任委员、北京加科思新药研发有限公司董事长兼CEO
WANG Yinxiang, Vice-Chairman of PhIRDA Drug R&D Specialty Committee, Chairman and CEO of Jacobio Pharmaceuticals
代雯, 华泰证券研究所A+H医药行业首席分析师
DAI Wen，Head of China/HK Healthcare, Huatai Securities
鲍海洁, 香港交易所董事总经理、市场拓展联席主管
Christina BAO, Managing Director, Co-Head of Sales & Marketing of HKEX
Conference Affairs Contact
